Unknown

Dataset Information

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.


ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) patients often have a poor 5-year event-free survival. The only T-ALL specific drug in clinical practice is nelarabine. A prodrug of the deoxyguanosine analog ara-G, nelarabine is a rationally designed agent selective for the treatment of T-cell malignancies. Originally approved for relapsed/refractory T-ALL, it is increasingly used in T-ALL therapy and is currently being evaluated in upfront treatment. Whilst the clinical use of nelarabine has been the topic of multiple review articles, a thorough overview of the preclinical data detailing the molecular underpinnings of its anti-leukemic activity is lacking, which is critical to inform mechanism-based use. Thus, in the present article we conducted a semi-systematic review of the literature and c

SUBMITTER: Hormann FM 

PROVIDER: S-EPMC11879874 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature